RAPID3 correlates with ESSPRI and other patient-reported outcomes in patients with primary Sjögren's syndrome

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):718. Epub 2017 May 15.

Authors

Marja Pertovaara¹, Markku Korpela²

Affiliations

¹ Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland and University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland. marja.pertovaara@uta.fi.
² Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland and University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland.

PMID: 28516885

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antirheumatic Agents / therapeutic use*
Arthralgia / drug therapy*
Arthralgia / etiology
Female
Glucocorticoids / therapeutic use*
Humans
Hydroxychloroquine / therapeutic use
Male
Methotrexate / therapeutic use
Middle Aged
Patient Reported Outcome Measures*
Sjogren's Syndrome / complications
Sjogren's Syndrome / drug therapy*
Surveys and Questionnaires

Substances

Antirheumatic Agents
Glucocorticoids
Hydroxychloroquine
Methotrexate